Last reviewed · How we verify
Vinorelbine, cyclofosfamide
At a glance
| Generic name | Vinorelbine, cyclofosfamide |
|---|---|
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vinorelbine, cyclofosfamide CI brief — competitive landscape report
- Vinorelbine, cyclofosfamide updates RSS · CI watch RSS
- Gustave Roussy, Cancer Campus, Grand Paris portfolio CI